{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05103683",
            "orgStudyIdInfo": {
                "id": "TORL123-001"
            },
            "organization": {
                "fullName": "TORL Biotherapeutics, LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "First in Human Study of TORL-1-23 in Participants With Advanced Cancer",
            "officialTitle": "A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants With Advanced Cancer",
            "acronym": "TRIO049",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "first-in-human-study-of-torl-in-participants-with-advanced-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-11-17",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-11-15",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-11-15",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-10-21",
            "studyFirstSubmitQcDate": "2021-10-21",
            "studyFirstPostDateStruct": {
                "date": "2021-11-02",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-15",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-17",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "TORL Biotherapeutics, LLC",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Translational Research in Oncology",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer"
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumor",
                "Ovarian Cancer",
                "Endometrial Cancer",
                "NSCLC"
            ],
            "keywords": [
                "claudin6"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 90,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Monotherapy Dose Finding - Part 1",
                    "type": "EXPERIMENTAL",
                    "description": "TORL-1-23",
                    "interventionNames": [
                        "Drug: TORL-1-23"
                    ]
                },
                {
                    "label": "Expansion as Monotherapy - Part 2",
                    "type": "EXPERIMENTAL",
                    "description": "TORL-1-23",
                    "interventionNames": [
                        "Drug: TORL-1-23"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "TORL-1-23",
                    "description": "antibody drug conjugate (ADC)",
                    "armGroupLabels": [
                        "Expansion as Monotherapy - Part 2",
                        "Monotherapy Dose Finding - Part 1"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence and severity of adverse events and serious adverse events",
                    "description": "Incidence and severity of adverse events, serious adverse events, according to NCI-CTCAE Version 5.0",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "Maximum Tolerated Dose (MTD)",
                    "description": "Highest administered dose with \\< 33% participants experiencing dose limiting toxicity (DLT) in the first 6 DLT evaluable participants",
                    "timeFrame": "28 Days"
                },
                {
                    "measure": "Recommended Phase 2 Dose (RP2D)",
                    "description": "Based on the maximum tolerated dose, cumulative safety, and pharmacokinetic data",
                    "timeFrame": "up to 2 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Objective Response Rate (ORR)",
                    "description": "Percentage of participants with best response of complete response (CR) or partial response (PR) according to RECIST 1.1",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "Duration of Response (DOR)",
                    "description": "Time from CR or PR to objective disease progression or death to any cause",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "Progression Free Survival (PFS)",
                    "description": "PFS is defined as the time from the start of the treatment until objective disease progression or death from any cause",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "Time to Response (TTR)",
                    "description": "Time from start of treatment to complete response or partial response",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "1 Year Overall Survival (1YOS)",
                    "description": "Proportion of participants alive at 1 year from the start of treatment to death from any cause",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "2 Year Overall Survival (2YOS)",
                    "description": "Proportion of participants alive at 2 years from the start of treatment to death from any cause",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "Number of anti-drug antibody (ADA) Positive Participants",
                    "description": "Immunogenicity will be measured by the number of participants that are ADA positive.",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "Maximum Serum Concentration of TORL-1-23 (Cmax)",
                    "description": "PK assessment",
                    "timeFrame": "21 days"
                },
                {
                    "measure": "Minimum Serum Concentration of TORL-1-23 (Cmin)",
                    "description": "PK assessment",
                    "timeFrame": "21 days"
                },
                {
                    "measure": "Maximum Serum Concentration of TORL-1-23 at Steady State (Cmax,ss)",
                    "description": "PK assessment",
                    "timeFrame": "63 days"
                },
                {
                    "measure": "Minimum Serum Concentration of TORL-1-23 at Steady State (Cmin,ss)",
                    "description": "PK assessment",
                    "timeFrame": "63 days"
                },
                {
                    "measure": "Time of Maximum Serum Concentration of TORL-1-23 (Tmax)",
                    "description": "PK assessment",
                    "timeFrame": "21 days"
                },
                {
                    "measure": "Time of Minimum Serum Concentration of TORL-1-23 (Tmin)",
                    "description": "PK Assessment",
                    "timeFrame": "21 days"
                },
                {
                    "measure": "Time of Minimum Serum Concentration of TORL-1-23 at Steady State (Tmin,ss)",
                    "description": "PK Assessment",
                    "timeFrame": "63 days"
                },
                {
                    "measure": "Terminal Half-life (t1/2) of Serum TORL-1-23",
                    "description": "PK Assessment",
                    "timeFrame": "63 days"
                },
                {
                    "measure": "Area under the Serum Concentration-Time curve from the time of dosing to the last measurable concentration (AUClast) for TORL-1-23",
                    "description": "PK Assessment",
                    "timeFrame": "21 days"
                },
                {
                    "measure": "Area under the Serum Concentration-Time curve from the time of dosing extrapolated to time infinity (AUCinf) for TORL-1-23",
                    "description": "PK Assessment",
                    "timeFrame": "63 days"
                },
                {
                    "measure": "Apparent volume of distribution during the terminal phase (Vz) of TORL-1-23",
                    "description": "PK Assessment",
                    "timeFrame": "63 days"
                },
                {
                    "measure": "Clearance (CL) of TORL-1-23",
                    "description": "PK Assessment",
                    "timeFrame": "63 days"
                },
                {
                    "measure": "Accumulation ratio (Rac) of TORL-1-23",
                    "description": "PK Assessment",
                    "timeFrame": "63 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Advanced solid tumor\n* Measurable disease, per RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Adequate organ function\n\nExclusion Criteria:\n\n* Has not recovered \\[recovery is defined as NCI CTCAE, version 5.0, grade \u22641\\] from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements\n* Received prior chemotherapeutic, investigational, or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of TORL-1-23\n* Progressive or symptomatic brain metastases\n* Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection\n* History of significant cardiac disease\n* History of myelodysplastic syndrome (MDS) or AML\n* History of another cancer within 3 years before Day 1 of study treatment, with the exception of basal or squamous cell carcinoma of the skin that has been definitively treated. A history of other malignancies with a low risk of recurrence, including appropriately treated ductal carcinoma in situ (DCIS) of the breast and prostate cancer with a Gleason score less than or equal to 6, are also not excluded\n* If female, is pregnant or breastfeeding",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Stephen Letrent, PharmD, PhD",
                    "role": "CONTACT",
                    "phone": "858-342-6652",
                    "email": "stephen.letrent@torlbio.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Stephen Letrent, PharmD, PhD",
                    "affiliation": "TORL Biotherapeutics, LLC",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "UCLA - JCCC Clinical Research Unit",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Gottfried Konecny, MD",
                            "role": "CONTACT",
                            "phone": "310-794-4955"
                        },
                        {
                            "name": "Gottfired Konecny, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "University of Minnesota",
                    "status": "RECRUITING",
                    "city": "Minneapolis",
                    "state": "Minnesota",
                    "zip": "55455",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Boris Winterhoff, MD, PhD",
                            "role": "CONTACT",
                            "phone": "612-624-8003"
                        },
                        {
                            "name": "Boris Winterhoff, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.97997,
                        "lon": -93.26384
                    }
                },
                {
                    "facility": "Mayo Clinic in Rochester",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55905",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Andrea Wahner Hendrickson, MD",
                            "role": "CONTACT",
                            "phone": "855-776-0015"
                        },
                        {
                            "name": "Andrea Wahner Hendrickson, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                },
                {
                    "facility": "Cleveland Clinic",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alex Adjei, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000016889",
                    "term": "Endometrial Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005831",
                    "term": "Genital Diseases, Female"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000005833",
                    "term": "Genital Neoplasms, Female"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000014594",
                    "term": "Uterine Neoplasms"
                },
                {
                    "id": "D000014591",
                    "term": "Uterine Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12974",
                    "name": "Ovarian Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M1704",
                    "name": "Carcinoma, Ovarian Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M19235",
                    "name": "Endometrial Neoplasms",
                    "asFound": "Endometrial Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8943",
                    "name": "Genital Diseases, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8945",
                    "name": "Genital Neoplasms, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M17342",
                    "name": "Uterine Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M17339",
                    "name": "Uterine Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4352",
                    "name": "Ovarian Cancer",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4354",
                    "name": "Ovarian Epithelial Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}